Senhwa Biosciences, Inc. (TPEX: 6492)
Taiwan
· Delayed Price · Currency is TWD 45.35
-0.30 (-0.66%)
Nov 22, 2024, 1:30 PM CST
Senhwa Biosciences Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1 | 1 | 1 | 0.55 | 0.62 | 0.3 | Upgrade
|
| Revenue Growth (YoY) | 0% | 0% | 81.82% | -10.86% | 105.67% | -59.07% | Upgrade
|
| Cost of Revenue | 0.49 | 0.45 | 0.5 | 0.23 | 0.27 | 0.26 | Upgrade
|
| Gross Profit | 0.51 | 0.55 | 0.51 | 0.32 | 0.35 | 0.04 | Upgrade
|
| Selling, General & Admin | 62.71 | 54.79 | 43.77 | 71.17 | 83.24 | 56.8 | Upgrade
|
| Research & Development | 248.42 | 256.87 | 312.85 | 275.47 | 276.37 | 337.03 | Upgrade
|
| Operating Expenses | 311.13 | 311.66 | 356.62 | 346.64 | 359.61 | 393.84 | Upgrade
|
| Operating Income | -310.62 | -311.11 | -356.12 | -346.32 | -359.26 | -393.8 | Upgrade
|
| Interest Expense | -0.61 | -0.54 | -0.54 | -0.53 | -0.26 | -0.34 | Upgrade
|
| Interest & Investment Income | 6.25 | 7.64 | 7.32 | 4.61 | 4.02 | 6.21 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.39 | 0.49 | -1 | 1.24 | 0.43 | -2.41 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.71 | - | 0.01 | 0.92 | 0.2 | 0.64 | Upgrade
|
| EBT Excluding Unusual Items | -297.88 | -303.52 | -350.34 | -340.06 | -354.87 | -389.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.93 | 8.04 | 2.08 | 1.52 | 0.49 | - | Upgrade
|
| Other Unusual Items | - | 0.43 | - | 10.2 | - | - | Upgrade
|
| Pretax Income | -295.95 | -295.05 | -348.26 | -328.35 | -354.38 | -389.7 | Upgrade
|
| Income Tax Expense | 1.26 | 1.26 | 1.37 | 0.91 | 0.5 | 1.72 | Upgrade
|
| Net Income | -297.21 | -296.31 | -349.63 | -329.26 | -354.88 | -391.43 | Upgrade
|
| Net Income to Common | -297.21 | -296.31 | -349.63 | -329.26 | -354.88 | -391.43 | Upgrade
|
| Shares Outstanding (Basic) | 89 | 89 | 89 | 90 | 79 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 89 | 89 | 89 | 90 | 79 | 74 | Upgrade
|
| Shares Change (YoY) | -0.15% | -0.00% | -0.50% | 13.49% | 6.06% | 0.07% | Upgrade
|
| EPS (Basic) | -3.34 | -3.32 | -3.92 | -3.67 | -4.49 | -5.26 | Upgrade
|
| EPS (Diluted) | -3.34 | -3.32 | -3.92 | -3.67 | -4.49 | -5.26 | Upgrade
|
| Free Cash Flow | -285.81 | -290.96 | -400.34 | -300.29 | -273.07 | -384.83 | Upgrade
|
| Free Cash Flow Per Share | -3.21 | -3.26 | -4.49 | -3.35 | -3.46 | -5.17 | Upgrade
|
| Gross Margin | 51.20% | 55.20% | 50.50% | 58.73% | 56.89% | 12.67% | Upgrade
|
| Operating Margin | -31061.80% | -31111.10% | -35611.50% | -62966.55% | -58226.74% | -131266.67% | Upgrade
|
| Profit Margin | -29720.70% | -29630.60% | -34963.20% | -59864.91% | -57516.69% | -130475.33% | Upgrade
|
| Free Cash Flow Margin | -28580.50% | -29095.90% | -40034.00% | -54597.64% | -44257.86% | -128275.67% | Upgrade
|
| EBITDA | -301.09 | -309.53 | -355.81 | -345.86 | -357.94 | -391.54 | Upgrade
|
| D&A For EBITDA | 9.52 | 1.58 | 0.31 | 0.46 | 1.32 | 2.27 | Upgrade
|
| EBIT | -310.62 | -311.11 | -356.12 | -346.32 | -359.26 | -393.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.